201 related articles for article (PubMed ID: 29602065)
1. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
3. KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance.
Gaillard S; Charasson V; Ribeyre C; Salifou K; Pillaire MJ; Hoffmann JS; Constantinou A; Trouche D; Vandromme M
Biol Open; 2021 May; 10(5):. PubMed ID: 34184733
[TBL] [Abstract][Full Text] [Related]
4. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
[TBL] [Abstract][Full Text] [Related]
5. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
[TBL] [Abstract][Full Text] [Related]
6. KDM5 lysine demethylases are involved in maintenance of 3'UTR length.
Blair LP; Liu Z; Labitigan RL; Wu L; Zheng D; Xia Z; Pearson EL; Nazeer FI; Cao J; Lang SM; Rines RJ; Mackintosh SG; Moore CL; Li W; Tian B; Tackett AJ; Yan Q
Sci Adv; 2016 Nov; 2(11):e1501662. PubMed ID: 28138513
[TBL] [Abstract][Full Text] [Related]
7. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
8. Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis.
Huang J; Jin S; Guo R; Wu W; Yang C; Qin Y; Chen Q; He X; Qu J; Yang Z
RNA; 2024 Mar; 30(4):435-447. PubMed ID: 38296629
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
10. A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.
Ren Z; Kim A; Huang YT; Pi WC; Gong W; Yu X; Qi J; Jin J; Cai L; Roeder RG; Chen WY; Wang GG
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217626
[TBL] [Abstract][Full Text] [Related]
11. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia.
Koca D; Hastar N; Engür S; Kiraz Y; Ulu GT; Çekdemir D; Baran Y
Turk J Haematol; 2020 Feb; 37(1):5-12. PubMed ID: 31833715
[TBL] [Abstract][Full Text] [Related]
13. Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21.
Dai B; Hu Z; Huang H; Zhu G; Xiao Z; Wan W; Zhang P; Jia W; Zhang L
Biochem Biophys Res Commun; 2014 Nov; 454(1):221-7. PubMed ID: 25450384
[TBL] [Abstract][Full Text] [Related]
14. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Hinohara K; Wu HJ; Vigneau S; McDonald TO; Igarashi KJ; Yamamoto KN; Madsen T; Fassl A; Egri SB; Papanastasiou M; Ding L; Peluffo G; Cohen O; Kales SC; Lal-Nag M; Rai G; Maloney DJ; Jadhav A; Simeonov A; Wagle N; Brown M; Meissner A; Sicinski P; Jaffe JD; Jeselsohn R; Gimelbrant AA; Michor F; Polyak K
Cancer Cell; 2018 Dec; 34(6):939-953.e9. PubMed ID: 30472020
[TBL] [Abstract][Full Text] [Related]
15. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
[TBL] [Abstract][Full Text] [Related]
16. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
17. Original Research: miR-194 inhibits proliferation and invasion and promotes apoptosis by targeting KDM5B in esophageal squamous cell carcinoma cells.
Cui G; Liu D; Li W; Li Y; Liang Y; Shi W; Zhao S
Exp Biol Med (Maywood); 2017 Jan; 242(1):45-52. PubMed ID: 27480251
[TBL] [Abstract][Full Text] [Related]
18. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
[TBL] [Abstract][Full Text] [Related]
19. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).
Wong PP; Miranda F; Chan KV; Berlato C; Hurst HC; Scibetta AG
Mol Cell Biol; 2012 May; 32(9):1633-44. PubMed ID: 22371483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]